Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

T. Macarulla · SciRah

Researcher profile · Semantic Scholar

T. Macarulla

Share profile

T. Macarulla — researcher profile on SciRah

h-index: 62
Works: 564
Citations: 20K

Most-cited papers

Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
A. Schram, Koichi Goto, Dong-Wan Kim, T. Macarulla +28 more
2025New England Journal of Medicine124 citations Open access
Semantic Scholar
Cholangiocarcinoma 2026: status quo, unmet needs and priorities
J. Banales, Pedro M. Rodrigues, S. Affò, J. B. Andersen +143 more
2025Nature reviews: Gastroenterology & hepatology93 citations Open access
Semantic Scholar
Tumor Treating Fields with gemcitabine and nab-paclitaxel for locally advanced pancreatic adenocarcinoma: randomized, open-label, pivotal phase 3 PANOVA-3 study
Hani M. Babiker, V. Picozzi, S. Chandana, B. Melichar +18 more
2025Journal of Clinical Oncology38 citations Open access
Semantic Scholar
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe
L. Rimassa, A. Lamarca, G. O'Kane, Julien Edeline +18 more
2025The Lancet Regional Health - Europe33 citations Open access
Semantic Scholar
Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.
W. Park, A. Kasi, A. Spira, Luis Paz-Ares Rodríguez +32 more
2026New England Journal of Medicine28 citations
Semantic Scholar
Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer
Shubham Pant, Jia Fan, Do-Youn Oh, H. Choi +20 more
2025JAMA Oncology14 citations Open access
Semantic Scholar
The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer.
C. Leonhardt, M. Adham, S. Bazarbashi, I. Ben-Aharon +63 more
2026The Lancet Oncology9 citations
Semantic Scholar
MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor–Resistant Cholangiocarcinoma and Attenuate the IFN Response
J. Wan, H. Saatcioglu, H. Ellis, E. Aguado-Fraile +21 more
2025Clinical Cancer Research9 citations Open access
Semantic Scholar
Opportunities and Approaches to Optimising Advanced Cholangiocarcinoma Outcomes in the Era of Targeted Therapies: A Narrative Review
T. Macarulla, Cindy Neuzillet, G. Prager, L. Rimassa +1 more
2025Oncology and Therapy9 citations Open access
Semantic Scholar
SEOM-GEMCAD-TTD clinical guidelines for biliary tract cancer (2025)
T. Macarulla, J. Adeva, M. T. Cano Osuna, A. Ruiz-Casado +6 more
2025Clinical and Translational Oncology8 citations Open access
Semantic Scholar
Claudin 18.2 expression in gastroesophageal adenocarcinoma: biomarker overlap and association with clinical outcomes in a European cohort
E. Terán, R. Pazo, L. Carità, M. Alsina +28 more
2026ESMO Open7 citations
Semantic Scholar
Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial
D. Melisi, T. Macarulla, C. de la Fouchardière, R. Pazo Cid +14 more
2025ESMO Open7 citations Open access
Semantic Scholar
HERIZON-BTC-302: A phase 3 study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC).
James J. Harding, T. Macarulla, Shubham Pant, Xiaotian Wu +2 more
2025Journal of Clinical Oncology7 citations Open access
Semantic Scholar
Genomic profiling unlocks new treatment opportunities for ampullary carcinoma
C. Fabregat-Franco, F. Castet, G. Castillo, M. Salcedo +5 more
2025ESMO Open7 citations
Semantic Scholar
Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarcinoma in Spain
R. Álvarez-Gallego, R. Pazo-Cid, Borja López de San Vicente, T. Macarulla +11 more
2025Therapeutic Advances in Medical Oncology6 citations Open access
Semantic Scholar
LAPIS: Randomized phase 3 trial of chemotherapy (CTX) with and without pamrevlumab (PAM) for locally advanced pancreatic cancer (LAPC).
V. Picozzi, K. Khan, P. Hammel, M. Reni +9 more
2025Journal of Clinical Oncology6 citations Open access
Semantic Scholar
Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301
G. Abou-Alfa, I. Borbath, S. Roychowdhury, L. Goyal +11 more
2026ESMO Open5 citations Open access
Semantic Scholar
Perineural invasion is a prognostic factor in cholangiocarcinoma, regardless of anatomical location: A systematic review and meta-analysis
S. Conti, N. Tissera, F. Castet, M. Basagaña-Farres +9 more
2026JHEP Reports5 citations Open access
Semantic Scholar
Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registry
T. Macarulla, A. Muñoz, E. M. de Castro, A. Castillo +20 more
2025ESMO real world data and digital oncology5 citations Open access
Semantic Scholar
Role of CNNM4 in the progression of cholangiocarcinoma: implications for ferroptosis and therapeutic potential
Maria Mercado-Gómez, Naroa Goikoetxea-Usandizaga, Alvaro Eguileor Giné, M. A. Merlos Rodrigo +45 more
2025Gut5 citations Open access
Semantic Scholar
Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma.
Rodrigo Entrialgo-Cadierno, Konstantina Morali, I. Feliu, Yingyun Wang +26 more
2026Cancer Cell4 citations Open access
Semantic Scholar
NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial
T. Macarulla, R. Cid, M. Womack, A. C. Gracián +16 more
2026ESMO Open4 citations Open access
Semantic Scholar
Multidisciplinary management of persistent severe cancer pain: a collaborative European approach
D. Dupoiron, M. Padilla, M. Iorfida, A. Falcón +11 more
2025Supportive Care in Cancer4 citations Open access
Semantic Scholar
Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative
J. Taieb, J. Seligmann, D. Modest, C. Girault +153 more
2025ESMO Open4 citations Open access
Semantic Scholar
Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer
François Ghiringhelli, Richard D. Kim, T. Macarulla, I. Moreno +20 more
2026Journal for ImmunoTherapy of Cancer3 citations Open access
Semantic Scholar
Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study
G. Manji, Vincent Chung, Do-Youn Oh, Jill Lacy +12 more
2026The Oncologist3 citations Open access
Semantic Scholar
Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy.
Xue-Song Zhao, Qian-Yun Hao, M. Alsina, D. Acosta +12 more
2025Cancer Treatment Reviews3 citations Open access
Semantic Scholar
Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors
R. Dienstmann, A. Vivancos, P. Nuciforo, S. Aguilar +18 more
2025ESMO Open3 citations
Semantic Scholar
Young-onset biliary tract cancers: Characteristics, treatment patterns, and patient outcomes
T. Pudlarz, A. Turpin, N. Tissera, M. Hilmi +19 more
2025JHEP Reports3 citations Open access
Semantic Scholar
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer.
F. Castet, C. Fabregat-Franco, J. Bridgewater, J. W. Kim +20 more
2025Journal of Hepatology3 citations Open access
Semantic Scholar
IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
J. Powderly, M. Imbimbo, A. Italiano, P. Martin-Romano +17 more
2025Cancer Research Communications3 citations Open access
Semantic Scholar
Response to Letter to the Editor: ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’
T. Macarulla, R. Cid, M. Womack, A. C. Gracián +16 more
2026ESMO Open2 citations Open access
Semantic Scholar
Clinical advancement in the management of mutant isocitrate dehydrogenase (IDH) cancers
John A. Bridgewater, G. Tabatabai, T. Macarulla, S. Stacchiotti
2026EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]2 citations Open access
Semantic Scholar
Comparative genomic landscape of acquired resistance in pancreatic cancer treated with pan-RAS or KRASG12C inhibitors.
F. Castet, Tian V. Tian, T. Macarulla
2025Annals of Oncology2 citations
Semantic Scholar
Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metastatic pancreatic cancer: The phase I/II randomized NAPAN trial.
A. Gehrels, E. Pijnappel, E. V. van Daalen, S. Casalino +8 more
2026European Journal of Cancer1 citations
Semantic Scholar
Landmark analysis of overall survival (OS) by objective response in patients (pts) with previously treated, advanced HER2-positive biliary tract cancer (BTC): Post hoc analysis of the HERIZON-BTC-01 trial.
James J. Harding, Jia Fan, Do-Youn Oh, H. Choi +16 more
2026Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Real-world outcomes of microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) biliary tract cancers (BTC).
M. Eluri, A. M. Muñoz Martín, Lian-Chun Xiao, Q. Kimana +4 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
A phase 2/3 randomized study of BMS-986504 with nab-paclitaxel (nab-P) and gemcitabine (GEM) in first-line (1L) metastatic pancreatic ductal adenocarcinoma (PDAC) with homozygous MTAP deletion ( MTAP -del): MountainTAP-30.
Shubham Pant, M. Ducreux, M. Ikeda, Xian-Jun Yu +5 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
Phase II study of durvalumab plus olaparib in patients with metastatic pancreatic cancer and DNA damage repair gene alterations.
F. Castet, R. García-Carbonero, M. Lobo, Eva Martínez de Castro +16 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
Epidemiological characterization of biliary tract cancer patients from the Spanish RETUD Registry.
T. Macarulla, F. Castet, Alfredo Castillo Trujillo, Ruth Vera +16 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study.
Do-Youn Oh, M. Ikeda, T. Macarulla, A. He +15 more
2026Journal of Hepatology1 citations Open access
Semantic Scholar
Off-label use of olaparib in uncommon tumor locations in patients with impaired homologous recombination genes.
Héctor Carlos García-Díaz, M. Larrosa-García, Javier Gómez-Alonso, M. Cruellas +4 more
2025Farmacia Hospitalaria1 citations Open access
Semantic Scholar
Concordance analysis between tumor tissue HER2 status by immunohistochemistry (IHC) and in situ hybridization (ISH) and a translational analysis of plasma ctDNA in patients (pts) with biliary tract cancer (BTC): An exploratory analysis from the phase 2 HERIZON-BTC-01 trial.
James J. Harding, J. W. Kim, Do-Youn Oh, Heung-Moon Chang +13 more
2025Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Evaluating the relative treatment efficacy of CD40 agonist mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) using unanchored indirect treatment comparisons (ITCs).
E. O'Reilly, T. Macarulla, Laetitia Dahan, I. Borbath +7 more
2025Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Sonic hedgehog inhibitor suppresses carcinoma associated fibroblasts to prime Gemcitabine/Nab-Paclitaxel and anti-CTLA4 immunotherapy as sequential first-line combination therapy in a Phase 1b/2 study in PDAC: NUMANTIA trial
V. S. Kalluri, B. Bockorny, E. Borobio, T. Macarulla +14 more
2025medRxiv1 citations
Semantic Scholar
Long-term survival in patients with pancreatic cancer treated with second-line liposomal irinotecan plus 5-fluorouracil/leucovorin: observations from Korea, Italy, and Germany
S. Lonardi, K. Potthoff, L. Procaccio, C. Yoo +3 more
2025ESMO gastrointestinal oncology1 citations Open access
Semantic Scholar
Abstract 7141: Final analysis of the randomized Phase 2 cohort of CM24 with nivolumab and chemotherapy in pancreatic cancer & potential serum biomarkers
T. Macarulla, M. Cecchini, R. García-Carbonero, T. Golan +16 more
2025Cancer Research1 citations
Semantic Scholar
MDM2 amplification in patients with biliary tract cancer in RETUD registry.
A. M. Muñoz Martín, F. Castet, Javier Soto Alsar, J. Adeva +11 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar
GEMINI-Perioperative (PeriOp) Gastric: A phase 2 study of novel agent-based combinations as PeriOp therapy for previously untreated, locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma.
Zi-Yu Li, D. Molena, Jeeyun Lee, K. Shitara +15 more
2026Journal of Clinical Oncology0 citations Open access
Semantic Scholar
Existing challenges in the management of cholangiocarcinoma in Spain
A. M. Muñoz Martín, A. Lamarca, J. Banales, M. Iglesias +1 more
2026Clinical and Translational Oncology0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

F. Castet×10
Invite
F. Castet — researcher profile on SciRah
J. Adeva×7
Invite
J. Adeva — researcher profile on SciRah
E. Van Cutsem×6
Invite
E. Van Cutsem — researcher profile on SciRah
Shubham Pant×6
Invite
Shubham Pant — researcher profile on SciRah

A. M. Muñoz Martín

×6

Invite

A. M. Muñoz Martín — researcher profile on SciRah

A. Hollebecque×5

Invite

A. Hollebecque — researcher profile on SciRah

Invite

Z. Wainberg — researcher profile on SciRah

Invite

J. Banales — researcher profile on SciRah

Invite

L. Rimassa — researcher profile on SciRah

Invite

D. Malka — researcher profile on SciRah

Invite

J. W. Kim — researcher profile on SciRah

J. Bridgewater×4

Invite

J. Bridgewater — researcher profile on SciRah